NEW YORK (Reuters Health)—Tocilizumab induced a slow and lasting remission after an ultra-short pulse (three days) of steroids in newly diagnosed giant cell arteritis (GCA) patients, a proof-of-concept trial shows.1
His early research on cytokines and glucocorticoids led Peter Villiger, MD, of Medical Center Monbijou, Bern, Switzerland, to find ways to reduce steroid use, he tells Reuters Health by email. “I have always been concerned about the potential problems of combination therapy with tocilizumab and glucocorticoids and was looking forward to substantially shortening the co-medication with steroids.”
His team went on to publish, among others, the first case series on tocilizumab for the treatment of GCA and the first randomized controlled trial of tocilizumab for induction and maintenance of remission in GCA using a very rapid reduction scheme of prednisone, he says.2,3
For the current study, Dr. Villiger and colleagues evaluated the efficacy and safety of tocilizumab monotherapy after ultra-short-term glucocorticoid treatment in patients with new-onset GCA. As reported in The Lancet Rheumatology, the single-arm, single-center, open-label, proof-of-concept GUSTO (giant cell arteritis treatment with ultra-short glucocorticoids and tocilizumab) trial enrolled 18 patients (median age: 72; 67%, women; 100% white).
Participants received 500 mg of intravenous (IV) methylprednisolone for three consecutive days only, followed by a single infusion of IV tocilizumab (8 mg/kg bodyweight) and weekly subcutaneous tocilizumab injections (162 mg) thereafter, until week 52.
The primary endpoint was the proportion of patients who experienced remission within 31 days and showed no relapse at week 24.
Overall, 15 of the 18 patients had cranial symptoms; 10 had polymyalgia rheumatica symptoms; and 13 showed a positive histopathology.
At 31 days, three (25%) of 12 patients were in remission. The null hypothesis could not be rejected, and the study was futile with respect to the primary endpoint.
However, 14 (78%) of 18 patients were in remission within 24 weeks (mean time to first remission 11.1 weeks) and 13 (72%) had no relapses up to 52 weeks. The mean time to the first partial remission was 6.2 weeks. No patients relapsed after induction of remission.
Overall, three did not respond to treatment and two discontinued the study due to an adverse event (hepatopathy in one and diverticulitis in the other). Anterior ischemic optic neuropathy occurred in one patient.
Dr. Villiger says, “The next study should be a multicenter trial testing a protocol for clinical use—i.e., co-medication with low-dose glucocorticoids over six weeks to control residual symptoms.”